AMPAC Fine Chemicals @ InformEx USA 2010

Published: 9-Feb-2010

Stand No 420, MR14


Ampac Fine Chemicals is a California-based cGMP custom manufacturer of Active Pharmaceutical Ingredients (APIs) and registered intermediates. AFC is a technology-based, fine chemical manufacturing company with demonstrated cGMP capabilities in process development, scale-up and production from kilogram to multi-ton scale using unique technologies.

We specialise in manufacturing of highly potent compounds (HPAPIs), handling of hazardous and energetic materials, continuous processing and continuous chromatography (SMB). We provide our customers with economical solutions to challenging problems using a blend of unique technology and expertise in process development and engineering developed over the past 50 years.
  • Companies:
  • AMPAC Fine Chemicals
  • Informa
See more

You may also like

Packaging

Contract packaging predicted to see high growth in 2024 ahead of Pharmapack Europe

Read more
Ninety four per cent of the industry are either "highly positive" or "moderately positive" about growth prospects for 2024

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Packaging

Contract packaging predicted to see high growth in 2024 ahead of Pharmapack Europe

Ninety four per cent of the industry are either "highly positive" or "moderately positive" about growth prospects for 2024
Packaging

Pharmapack: sustainability collaborations essential to mitigate scope 3 supply chain issues

Ahead of this month’s Pharmapack Europe 2024, Dr Kevin Robinson (KSR) spoke with Silvia Forroova (SF), Director of Partnerships and Sustainability at Informa Markets to find out how the event is helping the industry centralise debate and bring together different stakeholders in the supply chain to accelerate sustainable initiatives
Packaging

Global confidence in drug delivery innovation remains at record high, says Pharmapack

France sees biggest rise in delivery innovation score ahead of Pharmapack Europe 2024
Manufacturing

Pharma posts end-of-year bounce as CPHI Barcelona reports record attendance

More than 50,000 attendees at the world’s largest pharma event points to returning growth in 2024
Media

India pharma growth expectations in 2024 are the highest globally, say CPHI & PMEC India

More than 60% of the executives here are "highly positive" about 2024 — the highest of any country

Sustainability commitments accelerating in pharma supply chain, reveals CPHI report

80% of pharma execs state "sustainability metrics" and "sustainability goals" will be expected in contracts within just 2 years
Manufacturing

CPHI Annual Report predicts AI to transform all processes in drug development by 2026

The CPHI Annual Report 2023 will be available in full on October 23rd, featuring detailed insights from over 10 experts and the CPHI Annual Survey and Country rankings
Subscribe now